177 related articles for article (PubMed ID: 29194687)
21. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
22. Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer.
Moll JM; Teubel WJ; Erkens SE; Jozefzoon-Agai A; Dits NF; van Rijswijk A; Jenster GW; van Weerden WM
Front Oncol; 2022; 12():877613. PubMed ID: 35769712
[TBL] [Abstract][Full Text] [Related]
23. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
24. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
25. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
Takezawa Y; Izumi K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Kadono Y; Keller ET; Zhang J; Mizokami A
Anticancer Res; 2018 Apr; 38(4):2045-2055. PubMed ID: 29599322
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
[TBL] [Abstract][Full Text] [Related]
27. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
Filon MJ; Gillette AA; Yang B; Khemees TA; Skala MC; Jarrard DF
Prostate; 2022 Dec; 82(16):1547-1557. PubMed ID: 35980831
[TBL] [Abstract][Full Text] [Related]
29. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
[TBL] [Abstract][Full Text] [Related]
31. Androgen decreases osteoprotegerin expression in prostate cancer cells.
Vandyke K; Jackson P; Rowe A; Russell PJ; Blair JM
Prostate Cancer Prostatic Dis; 2007; 10(2):160-6. PubMed ID: 17189957
[TBL] [Abstract][Full Text] [Related]
32. Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues.
Arai S; Miyashiro Y; Shibata Y; Tomaru Y; Kobayashi M; Honma S; Suzuki K
Steroids; 2011 Feb; 76(3):301-8. PubMed ID: 21147140
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
34. Androgen quantitation in prostate cancer tissue using liquid chromatography tandem mass spectrometry.
Titus M; Tomer KB
Methods Mol Biol; 2011; 776():47-57. PubMed ID: 21796519
[TBL] [Abstract][Full Text] [Related]
35. Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c.
Lu X; Hsieh TC; Wu JM
Int J Oncol; 2004 Dec; 25(6):1801-7. PubMed ID: 15547720
[TBL] [Abstract][Full Text] [Related]
36. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
37. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
38. Lack of prostate cancer radiosensitization by androgen deprivation.
Pollack A; Salem N; Ashoori F; Hachem P; Sangha M; von Eschenbach AC; Meistrich ML
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1002-7. PubMed ID: 11704324
[TBL] [Abstract][Full Text] [Related]
39. A carbon 21 steroidal metabolite from progestin, 20β-hydroxy-5α-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
Ando T; Nishiyama T; Takizawa I; Miyashiro Y; Hara N; Tomita Y
Prostate; 2018 Feb; 78(3):222-232. PubMed ID: 29194690
[TBL] [Abstract][Full Text] [Related]
40. Biological effects of sex hormone-binding globulin on androgen-induced proliferation and androgen metabolism in LNCaP prostate cells.
Damassa DA; Lin TM; Sonnenschein C; Soto AM
Endocrinology; 1991 Jul; 129(1):75-84. PubMed ID: 2055206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
